Mode
Text Size
Log in / Sign up

ARDS subphenotypes may explain variable responses to neuromuscular blockade, corticosteroids, and prone positioningNew research explores personalized treatments for severe lung distress

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider ARDS subphenotypes as a framework for variable treatment response, but note the absence of quantitative estimates.

This systematic review synthesizes research on subphenotypes in acute respiratory distress syndrome (ARDS), using domains such as etiology, imaging, biomarkers, respiratory mechanics, and transcriptomics. The authors frame subphenotyping as a tool for prognostic and predictive enrichment, aiming to identify more homogeneous patient subgroups for precision medicine.

The key synthesized finding is that treatment responses to neuromuscular blockade, corticosteroids, and prone positioning vary across ARDS subphenotypes. However, the review does not report pooled effect sizes, absolute numbers, p-values, or confidence intervals for these differential responses. It highlights evidence for differential prognoses and treatment responses but does not provide specific trial data or statistical values.

The review offers a theoretical framework and practical guidance for advancing precision medicine in ARDS. It does not report safety data, adverse events, or tolerability. Limitations of the review are not reported, and funding or conflicts of interest are not disclosed.

For clinicians, the review suggests that ARDS subphenotypes may inform prognosis and treatment selection, but the absence of quantitative estimates means the differential treatment effects remain uncertain. Practice relevance is therefore conceptual rather than directly actionable.

How this fits prior evidence

This review extends prior coverage of corticosteroids in other conditions, such as anatomic regression of sarcoid-associated optic nerve head granuloma and first-line use in shrinking lung syndrome, by suggesting that corticosteroid responses in ARDS may differ across subphenotypes. It also contrasts with the broad first-line framing of corticosteroids in shrinking lung syndrome, emphasizing heterogeneity rather than uniform benefit. No prior coverage addresses ARDS subphenotypes or neuromuscular blockade, so this review addresses a gap in the publication's prior coverage.

When a patient suffers from acute respiratory distress syndrome (ARDS), their lungs struggle to provide enough oxygen. Currently, doctors often use a standard approach to treat this serious condition. However, new research suggests that patients might respond differently to common treatments like corticosteroids or neuromuscular blockade based on their specific illness type.

By looking at things like the cause of the illness, imaging, and biological markers, researchers are trying to group patients into smaller, more similar subgroups. This approach aims to move toward precision medicine, where the treatment is tailored to the specific needs of the patient's body rather than a one-size-fits-all method.

While the research shows that different treatments like prone positioning (laying a patient on their stomach) can have varying effects across these groups, it is still early. The study provides a framework for future care but does not provide specific trial data or exact numbers for how much better these treatments work for certain people.

What this means for you:
Identifying specific patient subgroups may help doctors choose the best treatments for severe lung distress.

Common questions

What is acute respiratory distress syndrome?

Acute respiratory distress syndrome, or ARDS, is a serious condition where the lungs are unable to provide enough oxygen to the body. It is a medical emergency that requires intensive care. This research looks at how to better treat patients suffering from this specific condition.

How does this research change current treatment?

The research provides a framework for precision medicine. Instead of treating everyone with the same method, it suggests that identifying specific patient subgroups based on their symptoms and biology can help doctors choose the most effective treatments, such as corticosteroids or neuromuscular blockade.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedOct 2026
View Original Abstract ↓
Acute respiratory distress syndrome (ARDS) is a highly heterogeneous critical illness syndrome lacking effective targeted therapies, partly due to the diverse patient population. Subphenotype research aims to identify homogeneous patient subgroups sharing common biological, physiological, or clinical characteristics, enabling prognostic and predictive enrichment. This review systematically summarizes current ARDS subphenotype research, from pathobiological mechanisms to multidimensional identification based on etiology, imaging, biomarkers, respiratory mechanics, and transcriptomics. We highlight evidence for differential prognoses and treatment responses across subphenotypes, including variable effects of neuromuscular blockade, corticosteroids, and prone positioning. We further discuss challenges and future directions in translating subphenotype classification into bedside practice. This article provides a theoretical framework and practical guidance for advancing precision medicine in ARDS.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.